Piper Sandler raised the firm’s price target on Day One Biopharmaceuticals (DAWN) to $26 from $25 and keeps an Overweight rating on the shares following quarterly results. The firm thinks valuation provides an attractive entry point into Day One ahead of continued commercial execution, additional long-term data, and eventual 1L pLGG data in 2027.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Biopharmaceuticals Reports Strong Q3 2025 Growth
- Day One Biopharmaceuticals Reports Strong Q3 2025 Results
- Day One Biopharmaceuticals reports Q3 EPS (19c), consensus (28c)
- Day One Biopharmaceuticals, Inc. (DAWN) Q3 Earnings Cheat Sheet
- Day One Biopharmaceuticals’ Phase 3 Trial: A Potential Game Changer in Pediatric Glioma Treatment